# Manteia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/manteia

- Industry: Healthcare IT
- Headquarters: Xiamen, China
- Website: www.manteiatech.com
- Total disclosed funding: $31M
- Latest round: Series B (Jan 18, 2024)
- Investors on record: 5

## About

Based in Xiamen, China and established in 2017, Manteia is a medical company that provides medical systems for adaptive radiation therapy. As of 2023, the company has passed the US FDA, China NMPA Class III, European CE and Korean KFDA product registration certification. In 2023, it develops and launches MOZI-Online TPS, the first plan design system that supports multiple guided images (CBCT/CT/MR). In January 2024,it raised a series B funding for CNY 110 million.

The company's main products include AccuContour (an intelligent radiotherapy image workstation), Online ART-TPS (an adaptive radiotherapy system) and ARTCheck (a real-time adaptive radiotherapy plan QA system).  In addition, AccuContour provides image analysis and radiomics tools. The company's products are used in clinical treatment and other fields. Its clients are the Mayo Clinic, the National Cancer Center & Proton Center (NCC) of Korea, Seoul National University Hospital (SNUH), Peking Union Medical College Hospital, and the General Hospital of the People's Liberation Army.

## Funding rounds

- Series B, Jan 18, 2024, $15M — Yangming Capital, Haichuang Tiancheng Capital
- Series A, Dec 28, 2020, $15M — DYEE Capital, Redhill Capital
- Angel, Apr 13, 2018 — Fosun International

## Investors

- Fosun International (https://capitalatlas.ai/funds/fosun-international) — Angel
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series A
- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Series A
- Yangming Capital — Series B
- Haichuang Tiancheng Capital (https://capitalatlas.ai/funds/haichuang-tiancheng-capital) — Series B